Targeting G protein-coupled receptors with biologics for therapeutic use, part 2

BioProcess International

Volumn 12, Issue 8, 2014, Pages

  Koglin, Markus ^a   Hutchings, Catherine J ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84908701480     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (24)

1. Koglin M, Hutchings CJ. Targeting G Protein-Coupled Receptors with Biologics for Therapeutic Use, Part 1. BioProcess Int. 12(6) 2014: 38-45.
2. Shemesh R, et al. Discovery and Validation of Novel Peptide Agonists for G Protein-Coupled Receptors. J. Biol. Chem. 283(50) 2008: 34643-34649.
3. Kasper AA, Reichert JM. Future Directions for Peptide Therapeutics Development. Drug Discov. Today 18(17-18), 2013: 807-817.
4. Yau MK, Liu L, Fairlie DP. Towards Drugs for Protease-Activated Receptor 2 (PAR2). J. Med. Chem. 56(19), 2013: 7477-7479.
5. Shao F, et al. Pharmacokinetic Study of Triptolide: A Constituent of Immunosuppressive Chinese Herb Medicine in Rats. Bio. Pharm Bull. 30(4), 2007: 702-707.
6. Adams MN. In Vitro and In Vivo Studies on Protease-Activated Receptor 2. PhD thesis. 2012. Queensland University of Technology, Brisbane, Queensland, Australia.
7. Carlson KE, McMurry TJ, Hunt SW III. Pepducins: Lipopeptide Allosteric Modulators of GPCR Signaling. Drug Discov. Today 9, 2012: 33-39.
8. Covic L, et al. Activation and Inhibition of G Protein-Coupled Receptors By Cell-Penetrating Membrane-Tethered Peptides. Proc. Natl. Acad. Sci. 99(2) 2002: 643-648.
9. Forsman H, et al. The Leukocyte Chemotactic Receptor FPR2, But Not the Closely Related FPR1, Is Sensitive to Cell-Penetrating Pepducins with Amino Acid Sequences Descending from the Third Intracellular Receptor Loop. Biochim. Biophys. Acta. 1833, 2013: 1914-1923.
10. Severino B, et al. Identification of a Pepducin Acting As a S1P3 Receptor Antagonist. J. Pept. Sci. 19(11) 2013: 717-724.
11. Quoyer J, et al. Pepducin Targeting the C-X-C Chemokine Type Receptor 4 Acts As a Biased Agonist Favouring Activation of the Inhibitory G Protein. Proc. Natl. Acad. Sci. 110(52) 2013: E5088-E5097.
12. Dandel M, et al. Immunoadsorption Therapy for Dilated Cardiomyopathy and Pulmonary Arterial Hypertension. Atherosclerosis Suppl. 14(1) 2013: 203-211.
13. Jahns R, et al. Targeting Receptor Antibodies in Immune Cardiomyopathy. Semin. Thromb. Hemost. 36(2) 2010: 212-217.
14. Münch G, et al. Administration of the Cyclic Peptide COR-1 in Humans (Phase 1 Study): Ex Vivo Measurements of Anti-ß1-Adrenergic Receptor Antibody Neutralization and of Immune Parameters. Eur. J. Heart Failure 14(11) 2012: 1320-1329.
15. Walter S, et al. Pharmacology of AMG 416 (Velcalcetide), A Novel Peptide Agonist of the Calcium-Sensing Receptor for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients. J. Pharmacol. Exp.Ther. 346(2) 2013: 229-240.
16. Woodnutt G, Violand B, North M. Advances in Protein Therapeutics. Curr. Opin. Drug Discov. Dev. 11(6) 2008: 754-761.
17. Shimamoto G, et al. Peptibodies: A Flexible Alternative Format to Antibodies. MAbs 4(5) 2012: 586-591.
18. Podust VN, et al. Extension of In Vivo Half-Life of Biologically Active Peptides via Chemical Conjugation to XTEN Protein Polymer. Protein Eng. Des. Sel. 26(11) 2013: 743-753.
19. Thundimadhathil J, et al. Cancer Treatment Using Peptides: Current Therapies and Future Prospects. J. Amino Acids 2012: 967347.
20. Jähnichen S, et al. CXCR4 Nanobodies (VHH-Based Single Variable Domains) Potently Inhibit Chemotaxis and HIV-1 Replication and Mobilize Stem Cells. Proc. Natl. Acad. Sci. 107(47) 2010: 20565-20570.
21. Wang F, et al. Reshaping Antibody Diversity. Cell 153(6) 2013: 1379-1393.
22. Milovnik P, et al. Selection and Characterization of DARPins Specific for the Neurotensin Receptor 1. Protein Eng. Des. Sel. 22(6) 2009: 357-366.
23. Cibiel A, Dupont DM, Ducongé F. Methods to Identify Aptamers Against Cell Surface Biomarkers. Pharmaceuticals 4 2011: 1216-1235.
24. Daniels D, et al. Generation of RNA Aptamers to the G-Protein Coupled Receptor for Neurotensin, NTS-1. Anal. Biochem. 305(2) 2002: 214-226.